Search
Spotlight
Global Oncology News
Join specialists as they discuss the lung cancer landscape
Live Broadcast: A New Treatment Option for Some Patients With Triple-Class Refractory Multiple Myeloma
Neoadjuvant HER2+
CAR-T Cell Therapy Learning Module
Global Oncology News
Join specialists as they discuss the lung cancer landscape
Live Broadcast: A New Treatment Option for Some Patients With Triple-Class Refractory Multiple Myeloma
Neoadjuvant HER2+
CAR-T Cell Therapy Learning Module
Specialty
View More
Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma
Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma
News
All Oncology News
Pipeline Report
Rare Cancer Series
All Oncology News
Pipeline Report
Rare Cancer Series
Media
Insights
Medical World News
News Network
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
Insights
Medical World News
News Network
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
State of the Science Summit / IPC
Webinars
Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Community
Interactive Tools
Learning Modules
Partners
Sponsored
Community
Interactive Tools
Learning Modules
Partners
Sponsored
Subscribe
eNewsletter
eNewsletter
Search
Spotlight
Global Oncology News
Join specialists as they discuss the lung cancer landscape
Live Broadcast: A New Treatment Option for Some Patients With Triple-Class Refractory Multiple Myeloma
Neoadjuvant HER2+
CAR-T Cell Therapy Learning Module
Specialty
See All >
Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma
Rapid Readouts: Initial Results of the Phase III BOSTON Study
June 29, 2020
Cristina Gasparetto, MD, Duke Cancer Institute
Cristina Gasparetto, MD, Duke Cancer Institute
Related Content:
Rapid Readouts
CAR T-cell Therapy
Rolling Submission to FDA Completed for Cilta-Cel for Relapsed/Refractory Multiple Myeloma
FDA Approval Sought for Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell ALL
Third-Line CAR T-Cell Therapy Improves Outcomes in B-Cell Lymphomas
Related Article >>>
x